The company is hoping to show GT-02287 can slow Parkinson's progression by restoring function of GCase, an enzyme encoded by ...
AstraZeneca has picked off another label expansion for its cancer blockbuster Imfinzi (durvalumab) as the FDA has ...
Pooled data analysis of efficacy and safety from Phase 2b and Phase 3 data sets in patients with early-stage Parkinson’s disease (PD) support ...
SOUTH SAN FRANCISCO, Calif., Dec. 05, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: DNLI) today announced initiation of dosing in a global Phase 2a clinical study, BEACON, of the investigational drug ...
Funding has been made available which will enable new research to take place into a possible link between manganese exposure ...
A team of international researchers led by Professor Johan Jakobsson at Lund University has secured a 52 million SEK grant from the Aligning Science ...
BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the first patient has been dosed with exidavnemab in the EXIST Phase 2a study, in Parkinson's disease patients. Exidavnemab is a ...
Director of public prosecutions Stephen Parkinson sets out plan to tackle crisis as massive rise in rape victim ‘attrition ...
Sleep fragmentation is a prevalent issue in Parkinson’s disease, significantly impacting quality of life and disease ...
New therapies that are less intrusive but more lasting than current interventions promise to arrest and even reverse neurodegeneration.